AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04252196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: usability evaluation of medical device
Description: participants interact with medical device and rate it for usability
Study NCT00924820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein over about 1 hour, every 2 weeks.
Study NCT06005077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal Massage Group
Description: While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
Study NCT06005077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal Warm Compress Application Group
Description: Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
Study NCT06005077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal Massage and Perineal Warm Compress Application Group
Description: When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
Study NCT00563602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic guided therapy
Description: To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)
Study NCT00563602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic guided therapy
Description: To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)
Study NCT03445663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 424
Description: Subjects will receive IV infusions of AMG 424
Study NCT01906762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
Study NCT01906762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
Study NCT02494882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT04347720 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: Intravenous and oral formulations
Study NCT02265393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTO-104
Study NCT02494882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT02494882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04437732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apioc-P and Apioc-PT Contact Lens Design
Description: Novel soft contact lens design
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
Study NCT03949634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
Study NCT04715321 — intervention group
Intervention type: OTHER
Intervention: CT perfusion examination
Description: CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
Study NCT01693328 — intervention group
Intervention type: DRUG
Intervention: PecFent® (fentanyl) nasal spray
Study NCT01782638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Study NCT01782638 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: deep brain stimulation
Study NCT01987570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study NCT03170700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition program with online parental feeding content
Description: Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
Study NCT01284517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Tablets 20-120 mg, PM dosing,daily for 6 weeks
Study NCT01284517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent to Lurasidone dosing
Study NCT03626792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypertensive group
Description: Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
Study NCT01886248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
Study NCT00515879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg
Study NCT00515879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT sessions aim to help participants become more comfortable with social situations.
Study NCT01987570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03179462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork intake
Description: Each participant will consume 2 ounces of cooked lean pork.
Study NCT03179462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed nuts intake
Description: Each participant will consume 1 ounce of mixed nuts.
Study NCT03179462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tofu intake
Description: Each participant will consume 2 ounces of tofu.
Study NCT04638218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training System
Description: The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
Study NCT03039829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine nitrate, low dose
Description: Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
Study NCT03039829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine nitrate, high dose
Description: Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
Study NCT03039829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at 6.0 grams (6.0 grams dextrose)
Study NCT02300272 — intervention group
Intervention type: DEVICE
Intervention: Polysomnograph
Description: Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
Study NCT02300272 — intervention group
Intervention type: DEVICE
Intervention: Actiwatch
Description: This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
Study NCT04491188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DE111
Description: 1 x10-9 CFU Bacillus subtilis DE111 probiotic
Study NCT04491188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study NCT03687580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Cure Laser Pro
Description: The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
Study NCT03687580 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
Study NCT00644527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purpose designed music and sound listening program
Description: Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
Study NCT00644527 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham music for depression
Description: Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
Study NCT00978120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine high dose
Description: 30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
Study NCT03626792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normotensive group
Description: Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
Study NCT02285335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GINST
Description: The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
Study NCT00978120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine low dose
Description: 15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
Study NCT04343508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified rice
Description: 100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
Study NCT04232761 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Drug administration as determined by treating physician
Study NCT00673712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Sternal Block
Description: Elastomeric Pump for Continuous Infusion of Local Anesthetic
Study NCT00673712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based analgesia
Description: Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN
Study NCT02435615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaniSal Oral Fluid Collector
Description: SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
Study NCT01855737 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Prescribe warfarin to the patients who are needed.
Study NCT01247649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical Logic Continuous Glucose Monitoring System
Description: Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
Study NCT01121224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
Study NCT01121224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent
Description: Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
Study NCT01121224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded clopidogrel
Description: For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
Study NCT01121224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
Study NCT01121224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thienopyridine (open-label)
Description: For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
Study NCT01121224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine (open-label)
Description: For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
Study NCT03598075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amylin (Pramlintide)
Description: Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
Study NCT03598075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CGRP
Description: CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vindesine
Description: 3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: 3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone tablets
Description: 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone tablets
Description: 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini Tablets
Description: 0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/㎡,one day before CHOP protocol
Study NCT02871869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/㎡,one day before CHOP protocol
Study NCT04270331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PADS protocol
Description: Assessment and management per PADS protocol
Study NCT00744068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing Care Telephone Support
Description: Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
Study NCT01574235 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nivestim®
Study NCT02825875 — intervention group
Intervention type: DRUG
Intervention: 18F DCFPyL- Radiopharmaceutica
Study NCT02042573 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS
Study NCT02042573 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SSRI (SEROPLEX ou ZOLOFT)
Study NCT02042573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genetic samples
Study NCT05069376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral Stent of 5-16 or 5-18
Description: Boston Scientific Polaris™ Ultra Ureteral Stent
Study NCT05959460 — intervention group
Intervention type: OTHER
Intervention: Deuterium dose-to-mother method for assessing breastfeeding
Description: Exclusive breastfeeding practice was compared between maternal recall and the deuterium dose-to-mother method.
Study NCT02754531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: USG
Description: USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
Study NCT02754531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cole Formula
Description: Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
Study NCT03158194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for anxiety-related asthma
Description: The specific assignments in the intervention will be based on individual behavior analysis for each participant.
Study NCT01450761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01450761 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Ipilimumab
Study NCT01450761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT01450761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Study NCT01450761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01450761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Study NCT01450761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01450761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study NCT01220739 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Laser Therapy
Description: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.